On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened higher 18.73% from the last session, before settling in for the closing price of $4.11. Price fluctuations for PHAT have ranged from $3.81 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1600.29%. Company’s average yearly earnings per share was noted 24.15% at the time writing. With a float of $38.70 million, this company’s outstanding shares have now reached $68.52 million.
Let’s determine the extent of company efficiency that accounts for 427 employees. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 44.53%, while institutional ownership is 60.24%. The most recent insider transaction that took place on Apr 07 ’25, was worth 16,740. In this transaction CFO and CBO of this company sold 3,678 shares at a rate of $4.55, taking the stock ownership to the 89,868 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Director bought 10,000 for $4.42, making the entire transaction worth $44,200. This insider now owns 85,500 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.15% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 1.08 million, which is a drop from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 23.98%. Additionally, its Average True Range was 0.68.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 17.34%, which indicates a significant decrease from 34.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 139.73% in the past 14 days, which was higher than the 96.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.51, while its 200-day Moving Average is $10.63. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $5.20. Second resistance stands at $5.51. The third major resistance level sits at $6.09. If the price goes on to break the first support level at $4.31, it is likely to go to the next support level at $3.73. Now, if the price goes above the second support level, the third support stands at $3.42.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 69,637K shares outstanding in the company with a market cap of 339.84 million. Presently, the company’s annual sales total 55,250 K according to its annual income of -334,330 K. Last quarter, the company’s sales amounted to 29,660 K and its income totaled -74,450 K.
